Telomir Pharmaceuticals
Update in progressTELO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Telomir Pharmaceuticals, Inc. is a preclinical biotechnology company developing small-molecule therapeutics aimed at upstream drivers of aging and age-related diseases. Its lead candidate, Telomir-1, is an oral metal ion regulator intended to protect against conditions such as Wilson’s disease, type 2 diabetes, AMD, oncology, epigenetic disorders, Alzheimer’s disease, and Progeria. Formerly Metallo Therapies, it renamed to Telomir in 2022. Incorporated in 2021 and based in Miami, Florida.
Company score
- Sentiment
- 0.24
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Erez Aminov
- Founded2021
- Websitetelomirpharma.com
Identifiers
- ISINUS87975F1049
- FIGIBBG01K4SG3V0
- CUSIP87975F104
- CIK0001971532